Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (1189)	9/21/1998 9:05:00 AM
From: BMcV	Read Replies (1) \| Respond to of 10280

Here's confirmation that Claritin DCL (now to be called "desloratadine" -- better by 5 syllables) is indeed in Phase III : biz.yahoo.com 09/21 07:17 Phase III Trials Underway for Desloratadine <SEPR.O><SGP.N> Phase III Trials Underway for Desloratadine MARLBOROUGH, Mass., Sept. 21 /PRNewswire/ -- Sepracor Inc. (Nasdaq: SEPR) today announced that Schering-Plough Corporation (NYSE: SGP) has initiated their Phase III program for desloratadine (previously referred to by Sepracor as descarboethoxyloratadine (DCL)). Desloratadine is an active metabolite of Schering-Plough's CLARITIN(R) brand of antihistamines, the world's leading nonsedating antihistamine, with 1997 sales of approximately $1.7 billion. In December 1997, Schering-Plough Corporation and Sepracor announced a licensing agreement giving Schering-Plough exclusive worldwide rights to Sepracor's patents relating to desloratadine, which in pre-clinical studies has shown the potential for greater potency. Under the terms of the agreement, Sepracor exclusively licensed its desloratadine related patent rights to Schering-Plough, which expects to develop and market a desloratadine product worldwide. Royalties paid to Sepracor will escalate over time and upon the achievement of sales volume and other milestones.